Related Experiment Video
Updated: Feb 15, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea
Joseph S Dillon1, Chandrikha Chandrasekharan2
1Division of Endocrinology, University of Iowa Hospital & VA Medical Center, Iowa City, IA 52242, USA.
Abstract:
Carcinoid syndrome (CS), characterized by diarrhea and flushing, is present in 20% of patients with neuroendocrine tumors at diagnosis and becomes more frequent with progression. The diarrhea of CS is caused mainly by tumoral secretion of serotonin. It may not be fully controlled by somatostatin analogs, the currently indicated drugs for symptomatic relief. Telotristat ethyl is a novel inhibitor of tryptophan hydroxylase, the rate-limiting enzyme in serotonin biosynthesis. Administration of the drug decreases diarrhea in patients with CS. Telotristat ethyl was approved in February 2017 (USA) and September 2017 (European Commission) for the treatment of CS diarrhea in adults inadequately controlled by somatostatin analog alone. This drug is expected to greatly improve the health and quality of life of patients with CS diarrhea.
More Related Videos
08:03Quantifying Vibrio cholerae Colonization and Diarrhea in the Adult Zebrafish Model
Published on: July 12, 2018
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Gene Therapy
Subviral Agents
Group Therapy
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction